Amgen Inc (AMGN)
298.68
-12.61
(-4.05%)
USD |
NASDAQ |
May 06, 11:12
Amgen SG&A Expense (Annual): 6.179B for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 6.179B |
December 31, 2022 | 5.414B |
December 31, 2021 | 5.368B |
December 31, 2020 | 5.73B |
December 31, 2019 | 5.15B |
December 31, 2018 | 5.332B |
December 31, 2017 | 4.87B |
December 31, 2016 | 5.062B |
December 31, 2015 | 4.846B |
December 31, 2014 | 4.699B |
December 31, 2013 | 5.184B |
December 31, 2012 | 4.814B |
December 31, 2011 | 4.499B |
December 31, 2010 | 3.983B |
December 31, 2009 | 3.82B |
December 31, 2008 | 3.789B |
December 31, 2007 | 3.361B |
December 31, 2006 | 3.366B |
December 31, 2005 | 2.79B |
December 31, 2004 | 2.556B |
December 31, 2003 | 1.957B |
Date | Value |
---|---|
December 31, 2002 | 1.449B |
December 31, 2001 | 970.70M |
December 31, 2000 | 826.90M |
December 31, 1999 | 654.30M |
December 31, 1998 | 515.40M |
December 31, 1997 | 483.80M |
December 31, 1996 | 470.60M |
December 31, 1995 | 418.40M |
December 31, 1994 | 359.80M |
December 31, 1993 | 583.70M |
December 31, 1992 | 397.40M |
December 31, 1991 | 443.70M |
March 31, 1991 | 257.20M |
March 31, 1990 | 134.60M |
March 31, 1989 | 23.00M |
March 31, 1988 | 10.30M |
March 31, 1987 | 6.80M |
March 31, 1986 | 22.00M |
March 31, 1985 | 17.30M |
March 31, 1984 | 11.00M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
5.15B
Minimum
2019
6.179B
Maximum
2023
5.568B
Average
5.414B
Median
2022
SG&A Expense (Annual) Benchmarks
Gilead Sciences Inc | 6.09B |
Johnson & Johnson | 20.11B |
Eli Lilly and Co | 6.941B |
Merck & Co Inc | 10.50B |
Vertex Pharmaceuticals Inc | 1.137B |